Business Context and Reporting Period
This Form 8-K was filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on March 6, 2021. The report details a material definitive agreement entered into on the same date involving AgeX, its subsidiary LifeMap Sciences, Inc. ("LifeMap"), Atlas Capital Partners Limited ("Atlas"), and GCLMS Acquisition Corporation ("Merger Sub").
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins for the reporting period. Instead, it outlines specific financial terms of the proposed merger:
- Total Cash Consideration: LifeMap shareholders will receive an aggregate cash payment of $500,000.
- Debt Conversion: $1,761,296.20 of LifeMap's indebtedness to AgeX will be converted into 32,556,306 shares of LifeMap common stock.
- Remaining Debt Payment: LifeMap will pay AgeX $250,000 in cash to settle the remaining portion of the indebtedness not converted into equity.
- Ownership Structure: AgeX currently holds approximately 80.74% of LifeMap. Following the debt conversion, AgeX's ownership is projected to increase to approximately 93.28% prior to the merger closing.
- Post-Merger Status: Upon consummation, LifeMap will cease to be a subsidiary of AgeX, and Atlas will become the sole shareholder and parent company of LifeMap.
Material Changes and Transaction Status
The primary material change is the divestiture of LifeMap Sciences, Inc. through a merger with a wholly-owned subsidiary of Atlas Capital Partners Limited. The transaction has been approved by the Boards of Directors of both AgeX and LifeMap, as well by holders of more than 80% of LifeMap's outstanding shares. The company expects the merger to close by March 15, 2021.
Outlook, Risks, and Contingencies
The completion of the merger is subject to several closing conditions, including:
- Obtaining necessary third-party consents under license agreements or contracts.
- Performance of obligations by all parties under the Merger Agreement.
- Accuracy of representations and warranties made by the parties.
Termination Rights: The agreement may be terminated by mutual consent, in the event of a material breach that is not cured, if closing conditions are not fulfilled by March 15, 2021, or if the transaction becomes illegal or is enjoined by a governmental authority.
Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from anticipated results due to various risk factors detailed in AgeX's periodic SEC reports.
Investor Verification Checklist
- Verify the final closing date of the merger, as the current expectation is March 15, 2021.
- Confirm the receipt of all required third-party consents for the transfer of LifeMap assets and licenses.
- Review the full text of the Plan and Agreement of Merger (Exhibit 10.1) for specific representations, warranties, and termination provisions.
- Monitor subsequent filings to confirm the final ownership percentage of LifeMap held by AgeX post-conversion and pre-merger.
- Assess the impact of LifeMap's divestiture on AgeX's future revenue streams and strategic focus.